CN1258372C - 治疗肠易激综合症的中药组合物及其制备方法 - Google Patents
治疗肠易激综合症的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN1258372C CN1258372C CN 200410014704 CN200410014704A CN1258372C CN 1258372 C CN1258372 C CN 1258372C CN 200410014704 CN200410014704 CN 200410014704 CN 200410014704 A CN200410014704 A CN 200410014704A CN 1258372 C CN1258372 C CN 1258372C
- Authority
- CN
- China
- Prior art keywords
- grams
- gram
- rhizoma atractylodis
- atractylodis macrocephalae
- pericarpium citri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 210000000936 intestine Anatomy 0.000 title abstract description 5
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title description 11
- 239000003814 drug Substances 0.000 claims abstract description 136
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000000341 volatile oil Substances 0.000 claims abstract description 37
- 239000000284 extract Substances 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 14
- 239000008158 vegetable oil Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000002481 ethanol extraction Methods 0.000 claims abstract description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 24
- 238000000108 ultra-filtration Methods 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- -1 filtered Substances 0.000 claims description 9
- 239000000084 colloidal system Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000010271 massa medicata fermentata Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 abstract description 42
- 239000008187 granular material Substances 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 7
- 238000000465 moulding Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000007902 hard capsule Substances 0.000 abstract description 4
- 239000000829 suppository Substances 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 4
- 241000132012 Atractylodes Species 0.000 abstract 4
- 241000675108 Citrus tangerina Species 0.000 abstract 4
- 241000229179 Ledebouriella Species 0.000 abstract 4
- 244000236658 Paeonia lactiflora Species 0.000 abstract 3
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 3
- 238000013329 compounding Methods 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 19
- 230000008485 antagonism Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000208340 Araliaceae Species 0.000 description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000008434 ginseng Nutrition 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940057995 liquid paraffin Drugs 0.000 description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000003871 intestinal function Effects 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229930003347 Atropine Natural products 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 229960002362 neostigmine Drugs 0.000 description 4
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 3
- 229910001626 barium chloride Inorganic materials 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical group O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000576 food coloring agent Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000016303 spleen symptom Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | n | 剂量(g/kg) | 小肠推进率(%) |
正常对照组谷参肠安组本发明药物低剂量组本发明药物中剂量组本发明药物高剂量组 | 1211121212 | 00.706.2018.6037.21 | 72.56±9.7466.72±11.2971.07±11.7165.92±9.8462.77±6.20** |
组别 | 剂量(g/kg) | 小肠推进率(%) |
正常对照组模型对照组谷参肠安组本发明药物低剂量组本发明药物中剂量组本发明药物高剂量组 | 000.706.2018.6037.21 | 69.18±8.5378.22±8.72△70.27±8.0673.02±11.7469.77±9.29*67.82±6.65** |
组别 | 剂量(g/kg) | 小肠推进率 |
正常对照组阿托品组谷参肠安组本发明药物低剂量组本发明药物中剂量组 | 000.706.2018.60 | 69.29±13.7753.11±12.9865.14±8.47*77.94±20.23**72.35±8.86** |
本发明药物高剂量组 | 37.21 | 76.65±13.27** |
本发明药物组别 | 浓度(mg/ml) | 正常幅度 | 加肠激舒后幅度 | 抑制率(%) |
低剂量组中剂量组高剂量组 | 8.2624.7849.56 | 4.52±0.404.27±0.694.27±0.69 | 3.63±0.813.29±0.38*2.46±0.75** | 19.6522.942.49 |
本发明药物组别 | 浓度(mg/ml) | 乙酰胆碱幅度 | 加本发明药物后幅度 | 拮抗率 |
低剂量组中剂量组高剂量组 | 8.2624.7849.56 | 6.08±0.775.81±1.505.24±1.22 | 5.38±0.794.39±0.732.92±0.37** | 11.4224.5344.2 |
本发明药物组别 | 浓度(mg/ml) | 组胺幅度 | 加本发明药物后幅度 | 拮抗率(%) |
低剂量组中剂量组高剂量组 | 8.2649.5624.78 | 4.14±0.614.29±0.723.89±0.37 | 3.19±0.65*3.42±0.50*2.51±0.39** | 22.8620.2335.36 |
本发明药物组别 | 浓度(mg/ml) | 氯化钡幅度 | 加本发明药物后幅度 | 拮抗率(%) |
低剂量组中剂量组高剂量组 | 8.2624.7849.56 | 4.66±0.554.99±0.804.85±1.06 | 3.82±0.30*3.22±0.71**2.59±0.36** | 18.1835.3946.6 |
组别 | 剂量(g/kg) | 木糖含量(g/l) |
正常对照组谷参肠安组本发明药物低剂量组本发明药物中剂量组本发明药物高剂量组 | 00.706.2018.6037.21 | 25.62±3.7823.14±6.4630.29±14.3631.44±4.43**26.05±9.29 |
组别 | 剂量(g/kg) | 动物数(n) | 冷冻3h(-20℃) | 脾指数 | |
死亡数 | 死亡率(%) | ||||
正常对照组模型对照组谷参肠安组本发明药物低剂量组本发明药物中剂量组本发明药物高剂量组 | 000.706.2018.6037.21 | 131413141313 | 2116513 | 15.3878.57**46.1535.717.69△△23.08△ | 0.47±0.0740.389±0.108*0.462±0.0950.479±0.062△0.507±0.134△0.499±0.093△△ |
组别 | 动物数(n) | 剂量(g/kg) | 冷冻3h(-20℃) | 脾指数 | |
死亡数 | 死亡率(%) | ||||
正常对照组模型对照组谷参肠安组本发明药物低剂量组本发明药物中剂量组 | 12791012 | 000.706.2018.60 | 37844 | 25100**88.8940△33.33△ | 0.508±0.0540.435±0.037**0.448±0.0420.488±0.048△0.551±0.122△ |
本发明药物高剂量组 | 12 | 37.21 | 3 | 25△△ | 0.518±0.098△ |
组别 | n | 体重(g) | 肝脾总重(g) | |
正常对照组谷参肠安组本发明药物低剂量组本发明药物中剂量组本发明药物高剂量组 | 91010810 | 24.71±4.1124.11±1.6225.7±2.5425.5±2.6725.67±6.71 | 1.307±0.3131.007±0.2851.167±0.1261.09±0.2231.048±0.222 | |
OD值 | K | a | ||
1min | 11min | |||
0.363±0.1310.525±0.1290.453±0.1390.507±0.124 | 0.211±0.1250.243±0.1650.188±0.1110.204±0.071 | 0.028±0.020.047±0.0380.045±0.0250.041±0.019 | 5.56±1.948.14±2.08*7.59±1.88*8.20±2.42* | |
0.578±0.194 | 0.186±0.128 | 0.053±0.019 | 9.86±4.45* |
组别 | 剂量(g/kg) | 动物数(只) | HC50 |
正常对照组谷参肠安组本发明药物低剂量组本发明药物中剂量组本发明药物高剂量组 | 00.706.2018.6037.21 | 9910910 | 26.064±11.14229.504±26.12944.688±26.6858.787±19.516*58.802±31.359 |
组别 | 剂量(g/kg) | 扭体次数 | 镇痛率(%) |
正常对照组阿司匹林组谷参肠安组本发明药物低剂量组本发明药物中剂量组本发明药物高剂量组 | 00.600.706.2018.6037.21 | 32.9±7.539.9±5.93**27.3±10.2727.3±9.5126.2±5.12*27.1±6.95 | -69.9117.0217.0220.3617.63 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410014704 CN1258372C (zh) | 2004-04-20 | 2004-04-20 | 治疗肠易激综合症的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410014704 CN1258372C (zh) | 2004-04-20 | 2004-04-20 | 治疗肠易激综合症的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1562144A CN1562144A (zh) | 2005-01-12 |
CN1258372C true CN1258372C (zh) | 2006-06-07 |
Family
ID=34478540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410014704 Expired - Lifetime CN1258372C (zh) | 2004-04-20 | 2004-04-20 | 治疗肠易激综合症的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1258372C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101474275B (zh) * | 2008-11-11 | 2012-01-25 | 深圳海王药业有限公司 | “痛泻要方”中药提取物的制备方法和用途 |
CN102247459B (zh) * | 2010-05-18 | 2013-07-24 | 南京中科药业有限公司 | 一种治疗胃肠功能紊乱的中药组合物及其制备方法 |
CN102397372A (zh) * | 2011-11-17 | 2012-04-04 | 云南云药科技股份有限公司 | 一种药物组合物及制剂和其在治疗肠易激综合征中的应用 |
CN103127487A (zh) * | 2013-03-19 | 2013-06-05 | 刘华荣 | 一种治疗脑部手术后腹泻的中药组合物 |
CN105012846A (zh) * | 2015-08-10 | 2015-11-04 | 王艳娣 | 一种治疗小儿腹泻的中药组合物 |
CN105031604A (zh) * | 2015-09-19 | 2015-11-11 | 庞群 | 激燥性大肠症及其治疗药物 |
-
2004
- 2004-04-20 CN CN 200410014704 patent/CN1258372C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1562144A (zh) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1233387C (zh) | 一种治疗失眠症的中药复方制剂及其制备方法 | |
CN1947757A (zh) | 地黄叶提取物及其制备方法和用途、用该提取物制备的药物 | |
CN1840001A (zh) | 一种独活寄生合剂的制备方法 | |
CN1258372C (zh) | 治疗肠易激综合症的中药组合物及其制备方法 | |
CN1285358C (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN1872199A (zh) | 一种中药组合物及其制备方法 | |
CN1895462A (zh) | 一种治疗前列腺炎的男康软胶囊 | |
CN1823870A (zh) | 一种南蛇藤中成药及其在抗类风湿关节炎中的应用 | |
CN1186051C (zh) | 一种化痰止咳的药物及其生产方法 | |
CN101036722A (zh) | 一种缓解疲劳、改善男性更年期综合征的保健食品及制备 | |
CN1899536A (zh) | 一种治疗糖尿病肾病的药物及其制备方法 | |
CN100341540C (zh) | 独活寄生颗粒及其制备方法 | |
CN1537544A (zh) | 一种降脂组合物及其制备方法 | |
CN100339101C (zh) | 藿香正气滴丸的制备方法及其用途 | |
CN1562337A (zh) | 治疗肾阳虚的中药及其制备方法 | |
CN1562113A (zh) | 一种治疗慢性盆腔炎的药物及其制备方法 | |
CN1857385A (zh) | 一种治疗颈椎病的药物组合物及其制备方法 | |
CN1803182A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN1194743C (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法和质量控制方法 | |
CN1257737C (zh) | 治疗偏头痛的中药组合物及其制备方法 | |
CN101062314A (zh) | 一种治疗痛风的药物及其制备方法 | |
CN1415318A (zh) | 一种用于治疗糖尿病的中药制剂及制备方法 | |
CN1679693A (zh) | 一种治疗肝病的药物及其制备方法 | |
CN1853670A (zh) | 冠心丹参微丸制剂及其制备方法 | |
CN1042395C (zh) | 蚁王精口服液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU KANGCHEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BIOLOGICAL ENGINEERING + MEDICINES TECH DEVELOPMENT CO., LTD., NANJING Effective date: 20050225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050225 Address after: 510530, Guangzhou economic and Technological Development Zone, Eastern District Dongpeng Avenue No. 71 Applicant after: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. Address before: 301 room 15, building 210032, hi tech Development Zone, Jiangsu, Nanjing Applicant before: NANJING B & M SCIENCE AND TECH |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: KANGYUAN PHARMACEUTICAL INDUSTRIAL CO LTD, INNER M Free format text: FORMER OWNER: KANGCHEN PHARMACEUTICAL CO., LTD., GUANGZHOU Effective date: 20121218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: GUANGZHOU, GUANGDONG PROVINCE TO: 028100 TONGLIAO, INNER MONGOLIA AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121218 Address after: 028100 Inner Mongolia Tongliao kezuohouqi Ganqika Tiedong Patentee after: KANGYUAN PHARMACEUTICAL INDUSTRIAL Co.,Ltd. INNER MONGOLIA Address before: Guangzhou economic and Technological Development Zone, Eastern District Dongpeng Avenue No. 71 Patentee before: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151225 Address after: 028100 the Inner Mongolia Autonomous Region Tongliao kezuohouqi Ganqika Industrial Park No. 2 North Road Patentee after: Kangchen Pharmaceutical (Inner Mongolia) Co.,Ltd. Address before: 028100 the Inner Mongolia Autonomous Region Tongliao kezuohouqi Ganqika Tiedong Patentee before: KANGYUAN PHARMACEUTICAL INDUSTRIAL Co.,Ltd. INNER MONGOLIA |
|
CX01 | Expiry of patent term |
Granted publication date: 20060607 |
|
CX01 | Expiry of patent term |